No Detail Found!

Pharmacokinetic and bioequivalence studies of immediate release Diclofenac Potassium tablets (50mg) in healthy volunteers.

Author(s)
Huma Ali Department of Pharmaceutics, Faculty of Pharmacy, University of Karachi, Karachi, Pakistan; Faculty of Pharmacy, Ziauddin University, Karachi, Pakistan
Muhammad Harris Shoaib Department of Pharmaceutics, Faculty of Pharmacy, University of Karachi, Karachi, Pakistan
Farya Zafar Faculty of Pharmacy, Ziauddin University, Karachi, Pakistan
Muhammad Hanif Department of Pharmaceutics, Faculty of Pharmacy, University of Karachi, Karachi, Pakistan
Rabia Bushra Department of Pharmaceutics, Faculty of Pharmacy, University of Karachi, Karachi, Pakistan
Asia Naz Department of Pharmaceutics, Faculty of Pharmacy, University of Karachi, Karachi, Pakistan
Raheela Khursheed Faculty of Pharmacy, Ziauddin University, Karachi, Pakistan
Abstract
This study was conducted with the aim to determine the pharmacokinetic and bioequivalence of diclofenac potassium 50 mg test (F4) tablet formulation with reference product (Caflam). Present study was single dose, randomized, two phase cross over design, conducted in 12 healthy Pakistani volunteers and planned in accordance with FDA guidelines. In this study a simple, selective, sensitive and reproducible HPLC procedure was developed and validated for the estimation of diclofenac potassium in plasma. The process was validated in the range of 50 - 0.05 µg.mL-1 and used in bioequivalence trial of two products. Multiple blood samples were collected at various time points (0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12 and 14 hr after treating volunteers with test (F4) and marketed reference brand. Plasma separation and deproteination were carried out with acetonitrile; samples (20µL) were injected using the validated HPLC method. Various pharmacokinetic parameters (compartmental and noncompartmental) were estimated using KineticaTM 4.4.1 (Thermo Electron Corp. USA). Bioequivalence among the products was established by calculating the 90% CI with log and non log transformed data for Cmaxcalc, Tmaxcalc, AUC0-∞, AUCtot and AUClast using two ways ANOVA and Schirmann’s Two one sided t-test. No significant difference was found between log and non-log data. The 90% confidence interval values using log transformed data for AUC0-∞ (0.997-1.024), AUCtot (1.004-1.031), AUClast (0.997 - 1.024), Cmaxcalc (0.994-1.007) and Tmaxcalc (0.996-1.013) for the trial and reference products were found within the FDA acceptable limits of 0.8-1.25. Results were further verified by the Schirmann’s one-sided t-test. Results showed the bioequivalence of test and reference formulations. Both the products were well tolerated.
Publication Details
Page(s) 1671-1679
DOI DOI not available
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 29, Issue: 5, Year: 2016

Request the full text from PASTIC

0

Citations

0

Downloads

192

Views